EUFOREA consensus on biologics for CRSwNP with or without asthma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F19%3AN0000049" target="_blank" >RIV/00064190:_____/19:N0000049 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/19:10409742
Result on the web
<a href="http://dx.doi.org/10.1111/all.13875" target="_blank" >http://dx.doi.org/10.1111/all.13875</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/all.13875" target="_blank" >10.1111/all.13875</a>
Alternative languages
Result language
angličtina
Original language name
EUFOREA consensus on biologics for CRSwNP with or without asthma
Original language description
Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent comorbidities, ensuring alleviation of both upper and lower airway pathology by systemic biological therapy. Type 2-targeting biologics such as anti-IgE, anti-IL4R alpha, anti-IL5, and anti-IL5R alpha have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patients. Given the high prevalence of chronic respiratory diseases and the high cost associated with biologics, patient selection is crucial in order to implement such therapies into chronic respiratory disease care pathways. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organized a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients with and without comorbid asthma.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30225 - Allergy
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
ALLERGY
ISSN
0105-4538
e-ISSN
1398-9995
Volume of the periodical
74
Issue of the periodical within the volume
12
Country of publishing house
US - UNITED STATES
Number of pages
8
Pages from-to
2312-2319
UT code for WoS article
000476166100001
EID of the result in the Scopus database
2-s2.0-85069662686